Table 3.
Clinical characteristics of the study groups after propensity score matching
| Clinical variables | Femoral access n = 62 | Carotid access n = 62 | Standardized difference | P value |
|---|---|---|---|---|
| Age, y | 83.5 (5.75)∗ | 83 (10.75)∗ | 0.034 | .97† |
| Male | 26 (41.9) | 33 (53.2) | 0.228 | .28‡ |
| Body mass index | 25 (4)∗ | 25 (7.75)∗ | 0.072 | .48† |
| COPD | 19 (30.6) | 23 (37.1) | 0.137 | .57‡ |
| NYHA class | 0.108 | .80‡ | ||
| 2 | 16 (25.8) | 19 (30.6) | ||
| 3 | 44 (71.0) | 41 (66.1) | ||
| 4 | 2 (3.2) | 2 (3.2) | ||
| Diabetes | 22 (35.5) | 19 (30.6) | 0.103 | .70‡ |
| eGFR, mL/min/1.73 m2 | 0.203 | .98‡ | ||
| >90 | 0 (0.0) | 1 (1.6) | ||
| >60-90 | 20 (32.3) | 22 (35.5) | ||
| >30-60 | 25 (40.3) | 24 (38.7) | ||
| >15-30 | 14 (22.6) | 12 (19.4) | ||
| <15 | 2 (3.2) | 2 (3.2) | ||
| Dialysis | 1 (1.6) | 1 (1.6) | ||
| Peripheral artery disease | 26 (41.9) | 28 (45.2) | 0.065 | .86‡ |
| Atrial fibrillation | 29 (46.8) | 27 (43.5) | 0.065 | .86‡ |
| Previous pacemaker | 11 (17.7) | 7 (11.3) | 0.184 | .45‡ |
| Coronary artery disease | 30 (48.4) | 29 (46.8) | 0.032 | 1.00‡ |
| Previous PCI | 20 (32.3) | 21 (33.9) | 0.034 | 1.00‡ |
| Previous CABG | 8 (12.9) | 10 (16.1) | 0.092 | .80‡ |
| SPAP, mm Hg | 0.250 | .66‡ | ||
| <25 | 30 (48.4) | 28 (45.2) | ||
| 25-31 | 15 (24.2) | 15 (24.2) | ||
| 31-55 | 16 (25.8) | 15 (24.2) | ||
| >55 | 1 (1.6) | 4 (6.5) | ||
| Mitral valve insufficiency | 14 (22.6) | 13 (21.0) | 0.039 | 1.00‡ |
| LVEF (%) | 58.5 (10.75)∗ | 55 (10)∗ | 0.077 | .40† |
| EuroSCORE II (%) | 4.95 (5.53)∗ | 5.55 (6.18)∗ | 0.171 | .17† |
Values are reported as counts and percentages or mean and standard deviation. COPD, Chronic obstructive pulmonary disease; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; SPAP, systolic pulmonary artery pressure; LVEF, left ventricular ejection fraction; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II.
∗
Median (interquartile ranges).
†
Unpaired Wilcoxon test.
‡
Fisher exact test.